Recombinant MS4A1 (Ocrelizumab Biosimilar) antibody
Research Grade
Reactivity: Human
ELISA
Host: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target
- MS4A1 (Ocrelizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
- Host
-
Mammalian Cells
- Expression System
- Mammalian cells
- Clonality
- Monoclonal
- Application
- ELISA
- Purpose
- Ocrelizumab Biosimilar - Anti-MS4A1, CD20 mAb
- Characteristics
- Antibody Type: IgG1-nd
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Grade
- Research Grade
- Isotype
- IgG1
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Storage
- -80 °C
- Storage Comment
- store at -80°C
-
- Target
- MS4A1 (Ocrelizumab Biosimilar)
- Target Type
- Biosimilar
- Background
-
2H7
Ocrelizumab is a CD20-directed cytolytic antibody, which is suitable for the treatment of patients with relapsed or primary progressive multiple sclerosis. It is a second-generation recombinant humanized monoclonal antibody of isotype IgG1 that can selectively target B lymphocytes expressing CD20 antigen. Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system, which can cause neurological dysfunction. Most patients with MS experience recurrent episodes with functional deterioration, followed by recovery or remission. - CAS-No
- 637334-45-3
-
You are here:
